Desano Pharmaceuticals Co., Ltd.

Overview

Desano Pharmaceuticals Co., Ltd. is a leading pharmaceutical company based in China. It focuses on the research, development, production, and marketing of pharmaceuticals, particularly in antiretroviral drugs and active pharmaceutical ingredients. Desano is well regarded for its contributions to HIV treatment and collaborates with numerous global health organizations.

Therapeutic areas

API / Drug Master Files

Desano Pharmaceuticals Co., Ltd. holds 12 active (13 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• TIZANIDINE HYDROCHLORIDEActive2026-03-30
• CELASTROLActive2026-02-08
• VENETOCLAX INTERMEDIATE (CAS NO.:1628047-87-9)Active2025-12-01
• VENETOCLAX INTERMEDIATE (CAS NO.:1228779-96-1)Active2025-12-01
• ACALABRUTINIB INTERMEDIATE (CAS NO.: 850568-25-1)Active2025-10-31
• ACALABRUTINIB INTERMEDIATE (CAS NO.: 1420478-88-1)Active2025-10-28
• BRIVARACETAMActive2023-07-26
• RIVAROXABANActive2023-01-17
• ELAGOLIX SODIUMActive2022-10-16
• ABT76Active2020-03-31
• ABT74Active2019-11-05
• LEVOCARNITINE USPActive2006-01-26
• VILDAGLIPTINInactive2021-12-15

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Desano Pharmaceuticals Co., Ltd. in our records. PharmaTek screens the full directory against live FDA enforcement data.